HR
HROW
HARROW, INC.
$33.00
+0.12%
$1.2B
No data for this timeframe.
Vol
Market Cap$1.2B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders7 funds
Inst. Value$131.0M
Inst. Activity3 buys / 0 sells
Insider Activity4B / 3S
Insider Net $-$7.4M
SEC Reports4
Press Releases2
Recent Activity
May 19, 2026
SEC
Harrow CEO Mark Baum, CFO Andrew Boll, and two directors collectively purchased $438K of stock in a 7-day cluster follow
CLUSTER — Impact 7/10
May 18, 2026
Insider
Graves Adrienne L bought 1,000 shares
Director @ $31.07 ($31.1K)
May 18, 2026
Insider
SILVERNAIL LAUREN P bought 1,000 shares
Director @ $31.00 ($31.0K)
May 15, 2026
Insider
Shojaei Amir sold 10,000 shares
CHIEF SCIENTIFIC OFFICER @ $0.00 ($0.00)
May 12, 2026
short_volume
Short Volume: HROW — 59.5% short (1.6M / 2.7M)
Short: 1,596,253 | Exempt: 87,376 | TRF Vol: 2,684,744 | Short Ratio: 59.5% | Off-exchange volume (d
May 11, 2026
SEC
Harrow reported Q1 2026 revenue of $44.2M (-8% YoY), missing consensus of $52.5M, and a GAAP net loss of $27.6M (-$0.74/
8-K — Impact 6/10
May 11, 2026
SEC
Harrow reported Q1 2026 revenue of $44.2M, down 7.6% YoY from $47.8M, and a GAAP net loss per share of -$0.74, significa
PRESS-RELEASE — Impact 6/10
Inst.
MORGAN STANLEY — ADD
233,755 shares ($11.5M)
Price Targets
$67.75
+105.3% upside
Strong Buy
Current $33.00
Low $59.00
Median $61.50
High $88.00
8 analysts
$59.00
$88.00
Analyst Ratings
5Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
| May 12, 2026 | BTIG | REITERATE | Buy → Buy |
| Apr 17, 2026 | BTIG | REITERATE | Buy → Buy |
| Apr 7, 2026 | B. Riley Securities | REITERATE | Buy → Buy |
| Mar 19, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.23 ▼ -1050.0% | $-0.50 — $0.01 | -196% YoY | 3 |
| Next Q | $0.36 ▼ -7.7% | $0.24 — $0.48 | 9% YoY | 3 |
| Current FY | $0.44 ▼ -32.8% | $0.24 — $0.56 | 3 | |
| Next FY | $2.68 ▼ -1.6% | $2.16 — $3.02 | 504% YoY | 3 |
Latest Reports
BULLISH
CLUSTER
7/10
Harrow CEO Mark Baum, CFO Andrew Boll, and two directors collectively purchased $438K of stock in a 7-day cluster follow
May 19, 2026
MIXED
8-K
6/10
Harrow reported Q1 2026 revenue of $44.2M (-8% YoY), missing consensus of $52.5M, and a GAAP net loss of $27.6M (-$0.74/
May 11, 2026
NEUTRAL
Press
3/10
Harrow, Inc. announced that three scientific abstracts featuring its ophthalmic products VEVYE® and ILEVRO® have been ac
Mar 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $94.2M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $13.4M | NEW |
| MORGAN STANLEY | $11.5M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $5.1M | TRIM |
| BANK OF AMERICA CORP | $4.7M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Graves Adrienne | BUY | $31.1K |
| May 18, 2026 | SILVERNAIL LAUREN | BUY | $31.0K |
| May 15, 2026 | Shojaei Amir | A | $0.00 |
| May 14, 2026 | BOLL ANDREW | BUY | $104.7K |
| May 14, 2026 | BAUM MARK | BUY | $302.0K |
7 institutional holders with $131.0M total value (2,672,508 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,921,683 | $94.2M | 71.9% | — |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 272,612 | $13.4M | 10.2% | NEW |
| 3 | MORGAN STANLEY | 233,755 | $11.5M | 8.7% | ADD +65.7% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 104,979 | $5.1M | 3.9% | TRIM -41.9% |
| 5 | BANK OF AMERICA CORP /DE/ | 95,359 | $4.7M | 3.6% | TRIM -47.0% |
| 6 | WELLS FARGO & COMPANY/MN | 39,112 | $1.9M | 1.5% | ADD +59.8% |
| 7 | FMR LLC | 5,008 | $245.4K | 0.2% | ADD +30.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 141,078 | 233,755 | +65.7% | $11.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 24,480 | 39,112 | +59.8% | $1.9M | 2025-Q4 |
| FMR LLC | ADD | 3,839 | 5,008 | +30.5% | $245.4K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 365,015 | 141,078 | -61.4% | $6.8M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 213,448 | 113,190 | -47.0% | $5.5M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 18,088 | 24,480 | +35.3% | $1.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 32,475 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 222,850 | 365,015 | +63.8% | $11.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 58,190 | 213,448 | +266.8% | $6.5M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 245,370 | 142,517 | -41.9% | $4.4M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 101,414 | 32,475 | -68.0% | $991.8K | 2025-Q2 |
| FMR LLC | TRIM | 4,959 | 3,498 | -29.5% | $106.8K | 2025-Q2 |
| UBS Group AG | TRIM | 178,367 | 125,892 | -29.4% | $3.3M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 150,355 | 101,414 | -32.6% | $2.7M | 2025-Q1 |
| FMR LLC | TRIM | 11,977 | 4,959 | -58.6% | $131.9K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 365,922 | 202,220 | -44.7% | $6.8M | 2024-Q4 |
| UBS Group AG | DOUBLED | 33,153 | 178,367 | +438.0% | $6.0M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 72,807 | 365,922 | +402.6% | $16.5M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 251,629 | — | $11.3M | 2024-Q3 |
7 unique insiders with 7 transactions. Net insider value: -$7.4M ($468.7K bought, $7.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Graves Adrienne L | Director | BUY | 1,000 | $31.07 | $31.1K |
| May 18, 2026 | SILVERNAIL LAUREN P | Director | BUY | 1,000 | $31.00 | $31.0K |
| May 15, 2026 | Shojaei Amir | CHIEF SCIENTIFIC OFFICER | A | 10,000 | $0.00 | $0.00 |
| May 14, 2026 | BOLL ANDREW R. | PRESIDENT AND CFO | BUY | 3,500 | $29.90 | $104.7K |
| May 14, 2026 | BAUM MARK L | CHIEF EXECUTIVE OFFICER | BUY | 10,000 | $30.20 | $302.0K |
| Mar 4, 2026 | Opaleye Management Inc. | 10%+ Owner | SELL | 134,000 | $39.67 | $5.3M |
| Mar 3, 2026 | Opaleye Management Inc. | 10%+ Owner | SELL | 59,000 | $39.15 | $2.3M |
| Feb 27, 2026 | Opaleye Management Inc. | 10%+ Owner | SELL | 5,000 | $54.18 | $270.9K |
| Jan 30, 2026 | Sullivan Patrick William | CHIEF COMMERCIAL OFFICER | A | 25,000 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 2 mixed, 1 neutral. Avg impact: 5.5/10.
BULLISH
CLUSTER
7/10
Harrow CEO Mark Baum, CFO Andrew Boll, and two directors collectively purchased $438K of stock in a
May 19, 2026
MIXED
8-K
6/10
Harrow reported Q1 2026 revenue of $44.2M (-8% YoY), missing consensus of $52.5M, and a GAAP net los
May 11, 2026
MIXED
PRESS-RELEASE
6/10
Harrow reported Q1 2026 revenue of $44.2M, down 7.6% YoY from $47.8M, and a GAAP net loss per share
May 11, 2026
NEUTRAL
DEFA14A
3/10
Harrow, Inc. has filed a definitive proxy statement (DEFA14A) for an upcoming shareholder meeting. T
Apr 24, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 5 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$67.75 mean target
+105.3% upside
Strong Buy (1.00)
$59.00 Low
$88.00 High
| Metric | Value |
|---|---|
| Current Price | $33.00 |
| Target Low | $59.00 |
| Target Mean | $67.75 |
| Target Median | $61.50 |
| Target High | $88.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.23 | $-0.50 | $0.01 | -195.8% | -1050.0% | 0↑ 1↓ | $0.1B | 11.3% | 3 |
| Next Q 2026-09-30 |
$0.36 | $0.24 | $0.48 | 9.1% | -7.7% | 1↑ 0↓ | $0.1B | 41.9% | 3 |
| Current FY 2026-12-31 |
$0.44 | $0.24 | $0.56 | — | -32.8% | — | $0.3B | 27.9% | 3 |
| Next FY 2027-12-31 |
$2.68 | $2.16 | $3.02 | 503.8% | -1.6% | 0↑ 2↓ | $0.5B | 48.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.230 | |
| 7d ago | $-0.020 | -0.210 |
| 30d ago | $-0.020 | -0.210 |
| 60d ago | $-0.020 | -0.210 |
| 90d ago | $0.260 | -0.490 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| May 12, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 17, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 7, 2026 | B. Riley Securities | REITERATE | Buy | Buy |
| Mar 19, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 18, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 4, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Mar 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
short_volume
Short Volume: HROW — 59.5% short (1.6M / 2.7M)
Short: 1,596,253 | Exempt: 87,376 | TRF Vol: 2,684,744 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings
Harrow Announces First Quarter 2026 Financial Results
<p align="justify"><strong>First Quarter 2026 and Selected Highlights: </strong></p>
May 11, 2026
earnings_calendar
HROW Q1 2026 Earnings Scheduled — 2026-05-11
Apr 29, 2026
FDA
FRESHKOTE LUBRICANT EYEDROPS, Sterile, 0.33 FL OZ (10mL), Harrow Eye LLC, Nashville, TN USA.
Class II: Lack of Assurance of Sterility
Apr 16, 2026
other
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
Reimbursement for Office-Based Utilization to Begin in July 2026 <pre>Reimbursement for Office-Based Utilization to Begin in July 2026</pre>
Apr 2, 2026
short_interest
FTD: HROW — 32,867 shares ($1.2M) failed to deliver
Settlement: 20260402, Price: $35.43, FTD Value: $1,164,477.81, HARROW INC COM STOCK
Apr 1, 2026
short_interest
FTD: HROW — 82,748 shares ($2.9M) failed to deliver
Settlement: 20260401, Price: $35.26, FTD Value: $2,917,694.48, HARROW INC COM STOCK
Mar 24, 2026
other
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
<p align="justify">NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management s
Mar 24, 2026
other
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
<p align="justify">NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management s
Mar 18, 2026
fda
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
<p>NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in Nort
Mar 18, 2026
FDA
IOPIDINE
Supplemental Approval — Labeling — APRACLONIDINE — SOLUTION/DROPS — OPHTHALMIC
Mar 18, 2026
FDA
IOPIDINE
Supplemental Approval — Labeling — APRACLONIDINE — SOLUTION/DROPS — OPHTHALMIC
Mar 10, 2026
short_interest
FTD: HROW — 23,521 shares ($0.8M) failed to deliver
Settlement: 20260310, Price: $35.15, FTD Value: $826,763.15, HARROW INC COM STOCK
Mar 4, 2026
other
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
<p align="justify">NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management s
Mar 4, 2026
short_interest
FTD: HROW — 133,013 shares ($5.1M) failed to deliver
Settlement: 20260304, Price: $38.61, FTD Value: $5,135,631.93, HARROW INC COM STOCK
Mar 2, 2026
earnings
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
<p align="justify"><strong>Fourth Quarter, Full-Year 2025 and Selected Highlights: </strong></p>
Mar 2, 2026
earnings_calendar
HROW Q4 2025 Earnings After Market Close — 2026-03-02
Mar 2, 2026
short_interest
FTD: HROW — 18,421 shares ($1.0M) failed to deliver
Settlement: 20260302, Price: $54.18, FTD Value: $998,049.78, HARROW INC COM STOCK